1. Scrip
  2. >>Business
  3. >>Earnings

Despite Flat Q2, Sanofi Foresees Growth In H2, Fuelled by IO And Rare Blood Units

 
• By Sten Stovall

CEO also says there's still room for more M&A, and that Sanofi is a virtual paragon of US pricing restraint that rivals can learn from.

SC1807_Bizman Telescope_662264896_1200.jpg
Sanofi CEO Sees Growth Coming, Boosted By Ablynx and Bioverativ Buys • Source: Shutterstock

Shrugging off further declines in its diabetes business during the second quarter, Sanofi's CEO Olivier Brandicourt used the French group's half-year update to predict a turnaround in the French group's fortunes starting with a resumption of growth in the second half, fueled not by price increases but rather by its rare blood disorder and new immunology businesses.

Presenting the second-quarter performance - which saw continued declines in its troubled diabetes segment that was largely offset by its Genzyme Corp. rare diseases division - Brandicourt said that as the impact from the US losses of exclusivity from key drugs peaked in the second quarter, "the growth of our diversified businesses largely compensated for these headwinds

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.